Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )

BACKGROUND: The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction. Empagliflozin reduces serum uric acid (SUA), but the relevance of this effect in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Doehner, Wolfram, Anker, Stefan D, Butler, Javed, Zannad, Faiez, Filippatos, Gerasimos, Ferreira, João Pedro, Salsali, Afshin, Kaempfer, Carolyn, Brueckmann, Martina, Pocock, Stuart J, Januzzi, James L, Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492270/
https://www.ncbi.nlm.nih.gov/pubmed/35788657
http://dx.doi.org/10.1093/eurheartj/ehac320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492270/
https://www.ncbi.nlm.nih.gov/pubmed/35788657
http://dx.doi.org/10.1093/eurheartj/ehac320

Ejemplares similares